Supportive Care in Low-Risk Myelodysplastic Syndromes: Role of Erythropoiesis Stimulating Agents (ESAs)

被引：0
|
作者：
Cerchione, Claudio [1 ]
Alfinito, Fiorella [2 ]
Giannini, Benedetta Maria [1 ]
Pane, Fabrizio [2 ]
Musuraca, Gerardo [1 ]
Martinelli, Giovanni [1 ]
机构：
[1] IRCCS, Hematol Unit, Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, FC, Italy
[2] AOU Federico II, Naples, Italy
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
MDS; myelodysplastic syndromes; ESAS; supportive; care; erythropoietin;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MDS-502
引用
收藏
页码：S318 / S318
页数：1
相关论文
共 50 条
  • [41] The role of hypomethylating agents prior to hematopoietic cell transplantation in myelodysplastic syndromes
    Sekeres, Mikkael A.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2018, 31 (04) : 346 - 350
  • [42] Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma
    Horvath-Puho, Erzsebet
    Suttorp, Marit M.
    Frederiksen, Henrik
    Hoekstra, Tiny
    Dekkers, Olaf M.
    Pedersen, Lars
    Cannegieter, Suzanne C.
    Dekker, Friedo W.
    Sorensen, Henrik Toft
    CLINICAL EPIDEMIOLOGY, 2018, 10 : 1371 - 1380
  • [43] The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances
    Randall, Michael P.
    DeZern, Amy E.
    CANCER JOURNAL, 2023, 29 (03) : 152 - 159
  • [44] A Systematic Literature Review of Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic Syndromes
    Boccia, Ralph
    Xiao, Hong
    von Wilamowitz-Moellendorff, Caroline
    Raorane, Renuka
    Deshpande, Sohan
    Klijn, Sven L.
    Yucel, Aylin
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (09)
  • [45] Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements
    Angel F. Remacha
    Beatriz Arrizabalaga
    Consuelo Del Cañizo
    Guillermo Sanz
    Ana Villegas
    Annals of Hematology, 2010, 89 : 147 - 154
  • [46] Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements
    Remacha, Angel F.
    Arrizabalaga, Beatriz
    Del Canizo, Consuelo
    Sanz, Guillermo
    Villegas, Ana
    ANNALS OF HEMATOLOGY, 2010, 89 (02) : 147 - 154
  • [47] Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes
    Vetro, Calogero
    Di Giacomo, Valeria
    Mannina, Donato
    Magrin, Silvana
    Mule, Antonio
    Mitra, Maria Enza
    Siragusa, Sergio
    Duminuco, Andrea
    Garibaldi, Bruno
    Vadala, Maria Cristina Emanuela
    Di Raimondo, Francesco
    Palumbo, Giuseppe A.
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (06)
  • [48] How low risk are low risk myelodysplastic syndromes?
    DeZern, Amy E.
    Dalton, William Brian
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (01) : 15 - 24
  • [49] Activity of Luspatercept and ESAs Combination for Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
    Al Ali, Najla
    Luis, Aguirre
    Onyee, Chan
    Kuykendall, Andrew
    Lancet, Jeffrey
    Padron, Eric
    Sallman, David
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S363 - S364
  • [50] Erythropoiesis in lower-risk myelodysplastic syndromes and beta-thalassemia
    Cappellini, Maria Domenica
    Taher, Ali T.
    Verma, Amit
    Shah, Farrukh
    Hermine, Olivier
    BLOOD REVIEWS, 2023, 59
12345